BR112013030991A2 - uso de gdc-0980 e método de tratamento de mesotelioma - Google Patents

uso de gdc-0980 e método de tratamento de mesotelioma

Info

Publication number
BR112013030991A2
BR112013030991A2 BR112013030991A BR112013030991A BR112013030991A2 BR 112013030991 A2 BR112013030991 A2 BR 112013030991A2 BR 112013030991 A BR112013030991 A BR 112013030991A BR 112013030991 A BR112013030991 A BR 112013030991A BR 112013030991 A2 BR112013030991 A2 BR 112013030991A2
Authority
BR
Brazil
Prior art keywords
gdc
use
treatment method
mesothelioma treatment
mesothelioma
Prior art date
Application number
BR112013030991A
Other languages
English (en)
Inventor
Jennifer O Hara Lauchle
Mika K Derynck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161492966P priority Critical
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to PCT/EP2012/060341 priority patent/WO2012164060A1/en
Publication of BR112013030991A2 publication Critical patent/BR112013030991A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
BR112013030991A 2011-06-03 2012-06-01 uso de gdc-0980 e método de tratamento de mesotelioma BR112013030991A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161492966P true 2011-06-03 2011-06-03
PCT/EP2012/060341 WO2012164060A1 (en) 2011-06-03 2012-06-01 Methods of treating mesothelioma with a pi3k inhibitor compound

Publications (1)

Publication Number Publication Date
BR112013030991A2 true BR112013030991A2 (pt) 2016-11-29

Family

ID=46210240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030991A BR112013030991A2 (pt) 2011-06-03 2012-06-01 uso de gdc-0980 e método de tratamento de mesotelioma

Country Status (11)

Country Link
US (1) US20120308562A1 (pt)
EP (1) EP2714046A1 (pt)
JP (1) JP2014515390A (pt)
KR (1) KR20140040728A (pt)
CN (1) CN103582479A (pt)
AR (1) AR086647A1 (pt)
BR (1) BR112013030991A2 (pt)
CA (1) CA2835760A1 (pt)
MX (1) MX2013014151A (pt)
RU (1) RU2013154355A (pt)
WO (1) WO2012164060A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
RU2637309C2 (ru) 2012-10-10 2017-12-04 Ф. Хоффманн-Ля Рош Аг Способ получения соединений тиенопиримидина
SG10201703977UA (en) * 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6581088B2 (ja) * 2013-12-12 2019-09-25 アルミラル・ソシエダッド・アノニマAlmirall, S.A. フマル酸ジメチルを含む医薬組成物
CA2966288A1 (en) * 2014-10-30 2016-05-06 Big Dna Ltd Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
KR20130058072A (ko) 2005-10-07 2013-06-03 엑셀리시스, 인코포레이티드 증식성 질환의 치료를 위한 mek 억제제로서의 아제티딘
ES2555154T3 (es) * 2006-08-14 2015-12-29 Sicor, Inc. Procesos para la preparación de intermedios del pemetrexed
TWI499420B (zh) * 2006-12-07 2015-09-11 Hoffmann La Roche 肌醇磷脂3-激酶抑制劑化合物及使用方法
US8247397B2 (en) * 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
ES2439705T3 (es) 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
US9042479B2 (en) 2008-10-16 2015-05-26 Qualcomm Incorporated Method and apparatus for avoiding interference between coexisting wireless systems
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック, インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用

Also Published As

Publication number Publication date
AR086647A1 (es) 2014-01-15
JP2014515390A (ja) 2014-06-30
RU2013154355A (ru) 2015-07-20
US20120308562A1 (en) 2012-12-06
MX2013014151A (es) 2014-01-23
WO2012164060A1 (en) 2012-12-06
EP2714046A1 (en) 2014-04-09
CN103582479A (zh) 2014-02-12
CA2835760A1 (en) 2012-12-06
KR20140040728A (ko) 2014-04-03

Similar Documents

Publication Publication Date Title
BR112013014863A2 (pt) método de cimentação, e, composição curável
BR112014017238A8 (pt) método e aparelho de configuração de ligação acelerada
BR112013015089A2 (pt) métodos e sistemas para incentivar a atividade atlética
BR112012003863A2 (pt) aparelho e método de processamento de informação, e, programa
BR112013030972A2 (pt) sistema e método para mensagens instantâneas seguras
BRPI1016218A2 (pt) sistema, e, método
BR112013002124A2 (pt) células e processo para a produção de ramnolipídeos
BR112013011412A2 (pt) aparelho de navegação e método
BR112013027378A2 (pt) nó b evoluído, equipamento de usuário, método implementado por computador e dispositivo de equipamento de usuário
BR112013009489A2 (pt) aparelho e método de conexão
BR112013022869A2 (pt) cápsula de entrega de bebida e métodos para uso e produção
BR112013002845A2 (pt) combinação de susbtâncias ativas
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
BR112013009069A2 (pt) instrumentação unida ao paciente e métodos
BR112012001213A2 (pt) aparelho de cortar cabelo e metodo de ultilização do aparelho de cortar cabelo
BRPI0924440A2 (pt) aparelho para restauração óssea da espinha e métodos de utilização
BR112013015325A2 (pt) utensílio e método para bebida preparada
BRPI1015350A2 (pt) anticorpos de anti-ceacam1 e métodos de usar os mesmos
BR112013014021A2 (pt) métodos para tratamento de calvície e promoção de crescimento de cabelos
BR112013002104A2 (pt) sistema e método de controle de semeadura
BR112013029079A2 (pt) dispositivo de rompimento do tecido e métodos correspondentes
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BR112013010750A2 (pt) detecção e atribuição de período de símbolo bariável
BRPI1011361A2 (pt) instalação de ordenha e método de operação da mesma

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)